Pars plana vitrectomy for the treatment of uveitis

• Verfasst von: Henry, Christopher R. [VerfasserIn]
• Verfasst von: Becker, Matthias D. [VerfasserIn]
• Verfasst von: Yang, Yongsheng [VerfasserIn]
• Verfasst von: Davis, Janet L. [VerfasserIn]
• Titel: Pars plana vitrectomy for the treatment of uveitis
• Verf.angabe: Christopher R. Henry, Matthias D. Becker, Yongsheng Yang, Janet L. Davis
• E-Jahr: 2018
• Jahr: 28 March 2018
• Umfang: 8 S.
• Fussnoten: Accepted 20 March 2018, Available online 28 March 2018 ; Gesehen am 18.12.2019
• Titel Quelle: Enthalten in: American journal of ophthalmology
• Ort Quelle: New York, NY : Elsevier Science, 1918
• Jahr Quelle: 2018
• Band/Heft Quelle: 190(2018), Seite 142-149
• ISSN Quelle: 1879-1891
• DOI: doi:10.1016/j.ajo.2018.03.031
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 168590372X

Abstract

Purpose - To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis. - Design - Systematic literature review. - Methods - A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed. - Results - Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Preoperatively, 157 of 300 (52%) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37%) postoperatively. Median use of oral corticosteroids improved from 48% preoperatively to 12% postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56% preoperatively to 36% postoperatively among the reporting studies. - Conclusions - Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.